[HTML][HTML] Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells
L Li, Q Li, ZX Yan, LS Sheng, D Fu, P Xu, L Wang… - Scientific reports, 2022 - nature.com
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising novel
therapeutic approach. However, primary and secondary resistance to CAR-T cell therapy is …
therapeutic approach. However, primary and secondary resistance to CAR-T cell therapy is …
[HTML][HTML] TCR redirected T cells for cancer treatment: achievements, hurdles, and goals
F Manfredi, BC Cianciotti, A Potenza, E Tassi… - Frontiers in …, 2020 - frontiersin.org
Adoptive T cell therapy (ACT) is a rapidly evolving therapeutic approach designed to
harness T cell specificity and function to fight diseases. Based on the evidence that T …
harness T cell specificity and function to fight diseases. Based on the evidence that T …
Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy
AB van der Waart, NMP van de Weem… - Blood, The Journal …, 2014 - ashpublications.org
Effective T-cell therapy against cancer is dependent on the formation of long-lived, stem cell–
like T cells with the ability to self-renew and differentiate into potent effector cells. Here, we …
like T cells with the ability to self-renew and differentiate into potent effector cells. Here, we …
Engineering IL-2 for immunotherapy of autoimmunity and cancer
R Hernandez, J Põder, KM LaPorte… - Nature Reviews …, 2022 - nature.com
Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …
[HTML][HTML] PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells
SB Lacher, J Dörr, GP de Almeida, J Hönninger… - Nature, 2024 - nature.com
Abstract Cancer-specific TCF1+ stem-like CD8+ T cells can drive protective anticancer
immunity through expansion and effector cell differentiation,,–; however, this response is …
immunity through expansion and effector cell differentiation,,–; however, this response is …
Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
SP Kerkar, P Muranski, A Kaiser, A Boni… - Cancer research, 2010 - AACR
T-cell–based immunotherapies can be effective in the treatment of large vascularized
tumors, but they rely on adoptive transfer of substantial numbers (∼ 20 million) of tumor …
tumors, but they rely on adoptive transfer of substantial numbers (∼ 20 million) of tumor …
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
NR Mathew, F Baumgartner, L Braun, D O'Sullivan… - Nature medicine, 2018 - nature.com
Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication
(ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after …
(ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after …
[HTML][HTML] CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck …
DM Kofler, M Chmielewski, G Rappl, A Hombach… - Molecular therapy, 2011 - cell.com
Adoptive T-cell transfer showed promising efficacy in recent trials raising interest in T cells
with redirected specificity against tumors. T cells were engineered with a chimeric antigen …
with redirected specificity against tumors. T cells were engineered with a chimeric antigen …
[HTML][HTML] Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Abstract Interleukin-2 (IL-2) is a component of most protocols of adoptive cell transfer (ACT)
therapy for cancer, but is limited by short exposure and high toxicities. NKTR-214 is a …
therapy for cancer, but is limited by short exposure and high toxicities. NKTR-214 is a …
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies
H Singh, MJ Figliola, MJ Dawson, H Huls, S Olivares… - Cancer research, 2011 - AACR
Improving the therapeutic efficacy of T cells expressing a chimeric antigen receptor (CAR)
represents an important goal in efforts to control B-cell malignancies. Recently an intrinsic …
represents an important goal in efforts to control B-cell malignancies. Recently an intrinsic …